Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Discovery of Eriodictyol as Putative Exportin-1 Inhibitor for Non-small Cell Lung Cancer Therapy

Version 1 : Received: 21 October 2020 / Approved: 23 October 2020 / Online: 23 October 2020 (10:19:32 CEST)

How to cite: Adigun, T.O.; Joel, I.Y.; Bankole, O.O.; Ambrose, G.O.; Medayedupin, O.A.; Omoyeni, O.C.; Agunlejika, A.A.; Ozojiofor, U.O.; Omoniyi, A.P.; Fakolujo, I.Y. Discovery of Eriodictyol as Putative Exportin-1 Inhibitor for Non-small Cell Lung Cancer Therapy. Preprints 2020, 2020100477 (doi: 10.20944/preprints202010.0477.v1). Adigun, T.O.; Joel, I.Y.; Bankole, O.O.; Ambrose, G.O.; Medayedupin, O.A.; Omoyeni, O.C.; Agunlejika, A.A.; Ozojiofor, U.O.; Omoniyi, A.P.; Fakolujo, I.Y. Discovery of Eriodictyol as Putative Exportin-1 Inhibitor for Non-small Cell Lung Cancer Therapy. Preprints 2020, 2020100477 (doi: 10.20944/preprints202010.0477.v1).

Abstract

Exportin-1, the ubiquitous nuclear protein transporter, is widely confirmed as an active chemotherapeutic target in non-small cell lung cancer condition while Juglans mandshurica is a well-studied anticancer plant in some lung cancer cell lines. We intend to find novel exportin-1 inhibitor from Juglans mandshurica with better potential tolerability and pharmaco-dynamo-kinetic properties than the current selective inhibitors of nuclear export in non-small cell lung cancer treatment. Osiris property explorer DataWarrior, Glide standard precision docking, quantum mechanics polarized ligand docking, MMGBSA binding free energy calculations, Jaguar density functional theory analysis, and the online web-based SwissADME were employed respectively in this study to filter the retrieved compounds based on tolerability, toxicity, and Lipinsky’s rule of five violation potential, determine their druggability, establish relative stability of the lead compound in water solvation model, and evaluates druglikeness, lead-likeness, as well as synthetic accessibility of the lead compound. This study reveals eriodictyol as having higher binding free energy (-40 kcal/mol) than that of standard (-39.56 kcal/mol) in exportin-1 active site, better synthetic accessibility score (3.15 versus 3.29), high GI absorption, non-blood brain barrier permeant, lacks Brenk and PAINS alert, obeying Lipinski’s, Ghose’s, Veber’s, Egan’s, and Muegge’s rule of druglikeness and lead-likeness as well as non-cytotoxic to HepG2 cells. We therefore found eriodictyol as a lead-like, non-toxic exportin-1 inhibitor with good predictive stability and pharmacokinetic potential and thus provided data for further validation of eriodictyol as a candidate exportin-1 inhibitor in both preclinical and clinical studies involving lung cancer therapy.

Subject Areas

Exportin-1; Eriodictyol; Juglans mandshurica; Non-small cell lung cancer

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.